Algen

Executive Summary

Algen is a pre-clinical biotechnology company leveraging CRISPR and machine learning to discover first-in-class drugs that modulate RNA messages at single-cell resolution, with initial focus on oncology and inflammation. Founded in 2020 by members of the Jennifer Doudna Lab and backed by Y Combinator (W2024), the company aims to unlock new therapeutic targets by precisely controlling RNA expression in specific cell types. While Algen has not yet disclosed its lead programs or financing rounds, its novel platform combining gene-editing tools with single-cell analytics positions it at the forefront of RNA-targeted therapeutics. The company's strength lies in its world-class scientific pedigree and the growing demand for precision medicines that address disease at the transcriptomic level. However, as a private, early-stage entity, Algen faces significant technical and regulatory hurdles before clinical validation. Its ability to secure Series A funding and demonstrate in vivo proof-of-concept will be critical near-term milestones. The conviction score reflects robust foundational science offset by early-stage risk and limited public information.

Upcoming Catalysts (preview)

• Q3 2026Series A funding announcement80% success
• Q4 2026Publication of in vivo proof-of-concept data70% success
• H1 2027Pharmaceutical partnership or collaboration50% success